AbbVie disclosed that it is in the final stage of negotiations to acquire clinical‑stage biotechnology firm Apogee Therapeutics in an all‑cash transaction valued at approximately $10.9 billion.
Deal Structure and Valuation
The proposed purchase price translates to a roughly 60 % premium over Apogee’s closing share price of $90.38 on June 18. Under the terms, AbbVie will pay cash for each outstanding share, positioning the offer among the most sizable biotech deals since AbbVie’s $63 billion Allergan acquisition in 2019. The transaction would be AbbVie’s largest since that landmark purchase, despite Apogee lacking any marketed products at present.
Strategic Rationale
Apogee’s pipeline centers on antibody‑based therapies for inflammatory disorders, with its lead candidate zumilokibart targeting the IL‑13 cytokine implicated in atopic dermatitis. Clinical data suggest that zumilokibart could be administered only twice a year, a stark reduction compared with existing treatments that require up to 26 injections annually. AbbVie aims to broaden its immunology portfolio by integrating this novel asset, which could enhance its competitive edge among investors seeking next‑generation biologics.
Investor and Market Response
Following the announcement, AbbVie’s ticker ABBV slipped more than 2 % on Friday, while Apogee’s shares (APGE) rose approximately 2 % in after‑hours trading. Analysts, including JPMorgan’s Chris Schott, maintained a Buy rating on AbbVie, signaling confidence among investors that the acquisition aligns with long‑term growth objectives. A formal press release is anticipated as early as Monday, June 22, though both companies have remained silent on the ongoing discussions.